



Markets
/
Stocks
/
nasdaq-acog
/

Alpha Cognition Inc

ACOG

View Detailed Chart

5.230USD

+0.170+3.36%

Close 04/25, 16:00（ET）Quotes delayed by 15 min

83.78MMarket Cap

LossP/E TTM



Alpha Cognition Inc

5.230

+0.170+3.36%

Company

Intraday

30m

Today

+3.36%

5 Days

+26.94%

1 Month

0.00%

6 Months

0.00%

Year to Date

0.00%

1 Year

0.00%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

BUY

Current Rating

20.000

Target Price

296.83%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

556

Total

Median

Average

Company name

Ratings

Analysts

Alpha Cognition Inc

ACOG

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Regeneron Pharmaceuticals Inc

REGN

Moderna Inc

MRNA

Exact Sciences Corp

EXAS

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(0)

Neutral(0)

Buy(2)

Indicators

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

RSI(14)

STOCH(KDJ)(9,3,3)

ATR(14)

CCI(14)

Williams %R

TRIX(12,20)

StochRSI(14)

Moving Average

Sell(0)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

News

More news coming soon, stay tuned...

Company

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

Company codeACOG

CompanyAlpha Cognition Inc

CEOMr. Michael Mcfadden

Websitehttps://www.alphacognition.com/